Ovarian cancer (OC) is the most common cause of gynecological cancer-related deaths in the U.S. The majority (~70%) are epithelial ovarian carcinomas; of these, most are high-grade serous OC. Surgical resection followed by chemotherapy ± bevacizumab remains the standard of care for 1st- and 2nd-line therapy, but PARP inhibitors have rapidly become the standard of care in the 1st- and 2nd-line maintenance and later-stage settings for platinum-sensitive disease. Current developments span multiple mechanisms of action and targets.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in ovarian cancer to help guide strategic and tactical commercial development decisions for market participants.